Overview: Gamma-Glutamyl Transferase TestIntroduction: The Gamma-Glutamyl Transferase Test measures gamma-glutamyl transpeptidase to assess liver or bile duct disorders, causing jaundice or fatigue. Aligned with 2023 AASLD guidelines, it uses an immunoassay for high sensitivity, aiding in liver function screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in biochemistry for patients with suspected liver conditions. Elevated GGT levels often indicate liver or bile duct issues, prompting further diagnostic workup. The test is widely used in clinical settings to monitor liver health, assess alcohol-related damage, and guide therapeutic interventions.
Other Names: GGTP Assay, GGT Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: GGT testing began in the 1960s with liver function research. Immunoassays emerged in the 1980s, improving accuracy for liver and bile duct disorders, with refinements in sensitivity by the 2000s.
Purpose: Diagnoses liver or bile duct disorders, guides treatment, and monitors GGT levels in patients with jaundice or fatigue.
Test Parameters: 1. Gamma Glutamyl Transpeptidase
Pretest Condition: Fasting for 10-12 hours required to stabilize enzyme levels. Collect serum or plasma in the morning. Report symptoms like jaundice or fatigue, and list medications, including alcohol use.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document jaundice, fatigue, or history of liver/bile duct disorders. Include current medications, especially hepatotoxic drugs or alcohol use, to contextualize results.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for liver treatment or lifestyle changes.
Procedural Considerations: Uses an immunoassay to measure GGT levels, Results are available in 1-2 days, enabling rapid clinical decisions. The test is often part of a liver function panel, enhancing diagnostic accuracy when combined with other markers.
Factors Affecting Result Accuracy: Non-fasting, hemolysis, or medications (e.g., alcohol, anticonvulsants) can elevate results. Renal disease or non-hepatic conditions may alter levels, requiring careful interpretation.
Clinical Significance: Elevated GGT levels suggest liver or bile duct disorders, prompting further testing or treatment. Normal levels may warrant additional evaluation to rule out other causes of symptoms.
Specialist Consultation: Consult a hepatologist or gastroenterologist for result interpretation and management planning.
Additional Supporting Tests: ALT, AST, bilirubin, alkaline phosphatase, or liver ultrasound to confirm liver/bile duct disorders and assess severity.
Test Limitations: Non-specific elevations may occur with alcohol use, medications, or non-hepatic conditions. Results require clinical correlation to ensure accurate diagnosis.
References: AASLD Liver Guidelines, 2023; Hepatology, Kwo PY, 2022.
